Home > Insider Trading > Filing (0000899243-20-020430)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1274792	Merrimack Pharmaceuticals Inc	MACK	()	UT

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1094201	L Gary Crocker	C/O Merrimack Pharmaceuticals, Inc. One Broadway 14Th Floor Cambridge MA 02142	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-07-22	17,000	$3.20	No	4	S	Direct
Common Stock	Disposition	2020-07-22	5,986	$3.04	No	4	S	Direct
Common Stock	Disposition	2020-07-22	8,428	$3.20	No	4	S	Direct
Common Stock	Disposition	2020-07-22	86,549	$3.04	No	4	S	Direct
Common Stock	Disposition	2020-07-22	52,068	$3.04	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-07-22	17,250	$3.20	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-07-22	6,228	$3.20	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Shares held directly by Reporting Person.
Shares held jointly with Reporting Person's wife.
Shares held directly by Reporting Person's wife.
Shares held by Crocker Family Investments, LLC, over which Reporting Person is the Managing Member.
Shares held by Crocker Ventures, LLC, over which Reporting Person is the President and Managing Member.
The sale of the securities referenced in this From 4 were conducted in a private transaction between Gary Crocker and certain family members and affiliates as the sellers and each of Western Standard Partners, L.P., Western Standard Partners QP, L.P., Newtyn Partners, LP, and Newton Partners TE, LP as the purchasers, regarding all shares of the Company over which he had dispositive control, along with the record owners of most of the shares of the Company over which Reporting Person had voting control. The purpose of the sale was to minimize tax liability by matching losses from these sales of Company stock with other investment gains. Gary Crocker is President and Chairman of Merrimack Pharmaceuticals, Inc. (the "Company"). Eric Andersen, a member of the Company's Board of Directors, is Managing Member of Western Standard LLC, the investment manager for each of Western Standard Partners L.P. and Western Standard Partners QP L.P.
(continued from footnote 6) Noah Levy, a member of the Company's Board of Directors, is Managing Member of Newtyn Management, LLC, the investment manager for Newtyn Partners, LP, and Newton Partners TE, LP.